46th Annual Meeting of the European Association for the Study of the Liver (EASL 2011)

March 30 - April 3, 2011, Berlin, Germany

Back EASL 2011

EASL 2011: Liver Disease Progression in HIV/HCV Coinfected People

Liver stiffness measured by FibroScan is a good predictor of liver cancer, end-stage liver disease or death among people with HIV/HCV coinfection, researchers reported as EASL 2011.

Read more:

EASL 2011: BMS-790052 + Pegylated Interferon/Ribavirin Works Well for First HCV Treatment

About 90% of treatment-naive genotype 1 hepatitis C patients achieved sustained response at 12 weeks post-treatment using the experimental HCV protease inhibitor BMS-790052 plus pegylated interferon/ribavirin, researchers reported at EASL 2011. alt

Read more:

HBV Genotype Predicts HBeAg Seroconversion on Tenofovir

Chronic hepatitis B patients with HBV genotype A and lower HBsAg levels at baseline were more likely to experience HBeAg seroconversion during treatment with tenofovir (Viread), researchers reported at EASL 2011. alt

Read more:

EASL 2011: BMS-790052/BMS-650032 Combo Cures Hepatitis C without Interferon

Most prior non-responders with HCV genotype 1 achieved sustained response with a quadruple combination containing 2 experimental agents plus pegylated interferon/ribavirin, and nearly 40% did so using only the 2 oral drugs -- BMS-790052 and BMS-650032 -- researchers reported at EASL 2011. 

Read more:

Immune-Based Therapy GS-9620 Shows Promise for Hepatitis B

Gilead's GS-9620, an experimental TLR7 agonist, stimulated interferon production and activated B-cells and T-cells in laboratory and human studies, and was active against hepatitis B and a related virus in monkeys and woodchucks, researchers reported at EASL 2011.

Read more: